Innovative medical technology company that focuses on the development and commercialization of soft tissue fillers selects clinivation WorldView as their enterprise solution for on-demand global regulatory intelligence.
Natick, MA, December 05, 2008 – clinivation, Inc. announced today that Contura International A/S has selected the clinivation WorldView enterprise solution for On-Demand Global Regulatory Intelligence.
“Contura is an innovative global leader in the development and commercialization of soft tissue fillers. We are pleased that they have chosen clinivation WorldView for comprehensive, authoritative, and up-to-date global regulatory intelligence,” said Richard Morroney, R.A.C., C.Q.A., clinivation’s Vice President of Quality and Regulatory Solutions.
About clinivation WorldView® On-Demand Global Regulatory Intelligence
Clinivation WorldView® is the medical device and diagnostic industry’s most comprehensive, authoritative, and up-to-date enterprise solution for On-Demand Global Regulatory Intelligence. Providing clear, step-by-step market clearance regulations, processes, and guidance for >99% of the world markets, only clinivation WorldView® delivers tried-and-true intelligence from certified, practicing professionals with real-world experience.
Contura International A/S
Headquartered in Copenhagen, Denmark, Contura is a medical technology company that develops and markets soft tissue fillers. Contura’s soft tissue fillers target both the medical and aesthetic markets. Two of the company’s main products are Aquamid® and Bulkamid®. Aquamid is a soft volume filler used to rejuvenate the face and enhance facial features. To date, plastic surgeons, dermatologists and cosmetic physicians have performed more than 300,000 Aquamid injections. Aquamid is available through a network of distributors covering 40 countries. Bulkamid is a urethral bulking agent used in the treatment of female urinary incontinence. Clinical studies have been performed in Europe and the FDA has granted Bulkamid an Investigational Device Exemption allowing it to be approved for clinical trials in the United States. Since 2007, ETHICON, a Johnson & Johnson company, has held exclusive worldwide distribution rights for Bulkamid, and the product is now available through ETHICON in Europe.
The company’s United States subsidiary office is in Jersey City, New Jersey.
For more information, please visit www.contura.com.
